From The Motley Fool · Prosper Junior Bakiny · · 1m
Moderna Stock to Lead Healthcare in 2026
Moderna's cancer vaccine breakthrough could make it the top healthcare stock by 2026 despite Wall Street skepticism.
In brief
Moderna's cancer vaccine breakthrough could make it the top healthcare stock by 2026 despite Wall Street skepticism. Moderna's personalized cancer vaccine shows promise but Wall Street expects a 45% price drop by 2032. Originally reported by The Motley Fool.
Moderna's 2026 Healthcare Potential
Moderna is expected to be the biggest healthcare winner among large-cap stocks in 2026.
Moderna's Recent Stock Performance
Moderna stock has dropped 17.57% to $202.63 after a 600% surge in 2026.
Cancer Vaccine Breakthrough
Moderna's investigational personalized cancer vaccine achieved a statistically significant improvement in recurrence-free survival.
“intismeran autogene achieved a statistically significant improvement in recurrence-free survival when combined with Merck's Keytruda”
mFLUSIVA Influenza Vaccine
Moderna received approval for mFLUSIVA, an influenza vaccine for people aged 50 and older.
Wall Street Skepticism
Wall Street expects Moderna's stock to drop 45% from current levels by 2032.
“Wall Street's average price target is $123.61, implying a 45% downside from current levels”
Financial Projections
Moderna needs $6.34 billion in net income by 2032 to meet Wall Street's expectations.
The key point
Moderna's personalized cancer vaccine shows promise but Wall Street expects a 45% price drop by 2032.
